secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001140361-25-039020
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics secures $4.0M from warrant exercise; GTx-104 PDUFA date set for April 23, 2026
--------------------------------------------------------------------------------

- Secured $4.0M via exercise of 1,345,464 common warrants at $3.003/share from September 2023 private placement.
- Remaining 1,190,927 warrants from the same placement expired after FDA accepted GTx-104 NDA for review.
- FDA set PDUFA target date of April 23, 2026 for GTx-104 NDA for aneurysmal subarachnoid hemorrhage (aSAH).
- GTx-104 is a novel injectable nimodipine formulation for I.V. infusion in aSAH patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125039020/0001140361-25-039020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125039020/ef20057547_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-039020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer